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Abstract Phenylketonuria (PKU, MIM 261600) is an
autosomal recessive disorder caused by mutations of the phe-
nylalanine hydroxylase gene (PAH, GenBank U49897.1,
RefSeq NM_000277). To date more than 560 variants of the
PAH gene have been identified. In Europe there is regional
distribution of specific mutations. Due to recent progress in
chaperone therapy, the prevalence of BH4-responsive alleles
gained therapeutic importance. Here we report the mutational
spectrum of PAH deficiency in 147 unrelated Austrian
families. Overall mutation detection rate was 98.6 %. There
was a total of 62 disease-causing mutations, including five
novel mutations IVS4+6T>A, p.H290Y, IVS8-2A>G,
p.A322V and p.I421S. The five most prevalent mutations
found in patients were p.R408W, IVS12+1G>A, p.R261Q,
p.R158Q and IVS2+5G>C. Neonatal phenylalanine levels
before treatment were available in 114/147 patients. Predic-
tion of BH4-responsiveness in patients with full geno-
types was exclusively made according to published data.
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Among the 133 patients needing dietary treatment,
28.4 % are expected to be BH4 "non-responsive",
4.5 % are highly likely BH4-responsive, 35.8 % are
probably BH4-responsive while no interpretation was
possible for 31.3 %. The mutation data reflect the
population history of Austria and provide information
on the likely proportion of Austrian PKU patients that
may benefit from BH4-therapy.
Introduction
Phenylketonuria (PKU, MIM 261600) is an autosomal reces-
sive disorder caused by alterations of the PAH gene
(NM_000277) coding for L-phenylalanine-4-hydroxylase
(PAH, EC 1.14.16.1). The PAH gene covers 120 kb on chro-
mosome 12q23.2 (DiLella et al. 1986). More than 560 differ-
ent gene variants are listed in the PAH mutation database at
www.pahdb.mcgill.ca (Scriver et al. 2003). In most Central
and Northern European countries 3–5 mutations account for
more than 50 % of PKU mutations in the population. The
majority (60 %) of mutations are missense mutations that
cause reduced or absent enzyme function by a variety of
pathogenetic mechanisms. Recently it has been shown that
effects on protein folding and degradation play a major path-
ogenetic role (Pey et al. 2007; Scriver 2007; Gersting et al.
2008). These effects can be studied by in vitro expression
studies (Erlandsen and Stevens 2001; Pey et al. 2003) and in
the in vivo mouse models Pahenu1/1 (Gersting et al. 2010) and
Pahenu1/2 (Lagler et al. 2010). Phenylalanine hydroxylase
function and response to BH4-administration result from an
interplay between genotype, metabolic state and cofactor con-
centration (Staudigl et al. 2011). Null mutations that com-
pletely abolish protein function include nonsense mutations
(5 % of recorded mutations), splice-site mutations (11 %),
small deletions (13 %), and small insertions (1 %). Large
deletions are generally rare (Møller et al. 2007) but have been
reported with a frequency of 3 % within Slavic population
(Kozak et al. 2006).
Most individuals affected with PKU are compound
heterozygotes carrying different mutations on both
alleles. In general, the mutation with higher residual
activity determines the overall enzyme function in an
individual patient (Gulderberg et al. 1998; Zurflüh et al.
2008); a hypomorphic mutation is described as “func-
tionally hemizygous” if there is a null mutation on the
other allele. Knowledge of the functional effects of two
mutations allows a prediction of the likely residual
enzyme function even in patients with novel genotype
combination, but there are still unknown factors that
influence the phenotype particularly in patients with
mild or moderate forms of PKU (Kayaalp et al. 1997;
Gulderberg et al. 1998).
The effect of BH4 responsiveness for some PAH missense
mutations has first been reported in 1999 (Kure et al. 1999). A
range of mechanisms is thought to contribute to this effect,
including chaperon-like activity of BH4 by preventing protein
misfolding and protection from inactivation of the mutant
protein (Pey et al. 2004), increasing PAH gene expression
(Munk-Martin and Hyland 2001), stabilization of misfolded
protein preventing premature decay of the misfolded protein
(Gersting et al. 2008) and increase of decreased BH4 binding
affinity of Km-variants of the PAH enzyme (Erlandsen and
Stevens 2001). The BIOPKU database www.bio-pku.org
provides preliminary information on BH4 responsiveness of
mutated PAH proteins collected in a non-standardized fashion
on a multicenter level. Proportion of patients with BH4 respon-
sive PKU based on BH4 tests was found to be 85 % (91/ 107)
in Italy (Fiori et al. 2005), 37 % (11/31) in Spain (Desviat et al.
2004), 46 % (17/37) in South Wales (Mitchell et al. 2005), and
in the Netherlands (86/186) (Anjema et al. 2011). Retrospec-
tive analysis of data on 1919 patients who underwent a BH4
loading test between 1988–2002 indicated that 70 % of
patients with neonatal phenylalanine levels <800 μmol/l were
found to be BH4-responders (Bernegger and Blau 2002).
In most European countries the spectrum of PKU
mutations in representative patient cohorts was deter-
mined in the 1990s (Zschocke 2003) but there are as
yet no such data for Austria. Here we report comprehen-
sive mutation analysis in a large cohort of PKU patients
treated in the four metabolic centers of Austria. Results
reflect the history of Austria as a central European country
with strong links to Eastern Europe and allow an estimation of
the likely proportion of patients that may benefit from BH4
therapy.
Material and methods
Genotype analysis of Austrian patients with PAH deficiency
started in 2004 at the laboratory of metabolic diseases,
Department of Pediatrics, Medical University of Graz and
since then was offered to all patients treated at the four
Austrian metabolic centers. The incidence of PKU in Austria
is approximately 1:12,000 (Kasper et al. 2010).
Subjects
A total of 168 patients from 147 unrelated families were
analysed. Patient numbers per center were as follows: Vienna
89, Graz 61, Salzburg 7, Innsbruck 11. Elevated phenylala-
nine concentrations were detected by newborn screening and
confirmed by quantitative analysis of plasma aminoacids.
Analysis of urinary pterins and dihydropterine reductase
assays were performed to exclude BH4 deficiency (Nenad
Blau, Zurich, Switzerland). For molecular studies, 3–5 ml of
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EDTA blood was drawn as part of regular blood sampling
after having obtained written informed consent of patients or
caregivers.
Methods
DNA-extraction was done from EDTA blood samples using
standard methods (QIAamp DNA Blood Mini Kit, QIAGEN,
Vienna, Austria). Over a period of 8 years (2004–2011) three
different methods were used with an over all detection rate of
98.6 %. Initially, restriction fragment length polymorphism
analysis (RFLP) for eight of the most frequent mutations of
PAH gene (GenBank U49897.1, RefSeq NM_000277) previ-
ously found in central Europe p.R408W (c.1222C>T),
p.R261Q (c.782G>A), p.Y414C (c.1241A>G), p.R158Q
(c.473G>A), IVS10-11C>T (c.1066-11G>A), IVS12+1G>A
(c.1315+1G>A), p.P281L (c.842C>T), p.I65T (c.194T>C) and
for several frequent polymorphisms p.Q232Q (c.696A>G),
p.V245V (c.735G>A), p.L385L (c.1155G>C), IVS3-22C>T
(c.353-22C>T) was performed; this method led to the char-
acterization of mutations on both alleles in 30 patients. In
the remaining samples mutation scanning was performed by
melting point (Tm) analysis using SYBR Green-labeled PCR
replicons of 100 bp-fragments, overlapping at a length of
12 bp, visualized in a ROCHE Light Cycler. Replicons with
aberrant melting points were sequenced in 21 cases. Subse-
quently (12/2004 to 12/2005) denaturing gradient gel elec-
trophoresis (DGGE) was used for mutation scanning in
another 29 patients following a previously published proto-
col (Zschocke et al. 2000). Since January 2006 another 67
samples were analyzed by complete sequencing of all exons
and 100 bp of flanking introns of the PAH gene.
Each of the DNA alterations in all 147 patients claimed
as a pathogenic change was confirmed by RFLP analysis.
The rarity of novel mutations was confirmed by compar-
ison with at least 110 wild type alleles. In silico-prediction
of pathogenicity of novel missense mutations was done with
the PolyPhen-2 bioinformational tool (http://genetics.bwh.
harvard.edu/pph2/) for the HumVar score and alignment
analysis. Splice site mutations were analyzed with SplicePort
(spliceport.cs.umd.edu) using a threshold of −0.5 for the
change of FGA (feature generation algorithm) score
(www.cbs.dtu.dk).
Four patients in whomwe had only identified one mutation
underwent additional MLPA (multiplex ligation-dependet
probe amplification) analysis (Zschocke, data not shown).
According to detailed information provided in the literature
(Pey et al. 2003 and 2004; Blau and Erlandsen 2004; Zurflüh
et al. 2008; Karacic et al. 2009) the genotype combination was
assigned to one of four groups:
1) “nonBH4 responsive” if both alleles showed null mutations
2) “BH4 responsive” if the patient carried a consistently
BH4 responsive mutation on at least one allele
3) “probably BH4 responsive” in the presence of at least
one mutation encoding a protein with known residual
activity but inconsistent information on BH4 response
Table 1 The 13 most prevalent mutations (GenBank U49897.1,
NM_000277) detected in 147 Austrian Phenylketonuria (PKU; MIM
261600) patients
Mutation Trivial name No. (percentage) of alleles
c.1222C>T p.R408W 67 (22.8 %)
c.1315+1G>A IVS12+1G>A 34 (11.6 %)
c.782G>A p.R261Q 20 (6.8 %)
c.473G>A p.R158Q 13 (4.4 %)
c.168+5G>C IVS2+5G>C 12 (4.1 %)
c.1241A>G p.Y414C 11 (3.7 %)
c.1066-11G>A IVS10-11G>A 11 (3.7 %)
c.1169A>G p.E390G 10 (3.4 %)
c.842C>T p.P281L 10 (3.4 %)
c.1066-3C>T IVS10-3C>T 8 (2.7 %)
c.165delT p.F55fs 7 (2.4 %)
c.143T>C p.L48S 5 (1.7 %)
c.1208C>T p.A403V 5 (1.7 %)
Total: 213 (72.4 %)
Fig. 1 Prediction of BH4 responsiveness according to full genotype in
our cohort of 147 Austrian patients with PAH deficiency (134 PKU, 13
MHP) according to published data (Pey et al. 2003 and 2004; Blau and
Erlandsen 2004; Zurflüh et al. 2008; Karacic et al. 2009). Group 1: non
BH4 responsive as both alleles show null mutations. Group 2: BH4
responsive as at least one allele is known to be consistent with BH4
responsiveness. Group 3: probably BH4 responsive as at least one
mutation is coding for a protein with known residual enzyme activity
but inconsistent information about BH4 responsiveness. Group 4:
unknown as information on residual activity or BH4 responsiveness
is pending. MHP- mild hyperphenylalaninaemia without the need of
dietary restriction; PKU- dietary restriction of daily phenylalanine
intake
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4) “unknown” if information on residual activity or BH4
responsiveness of at least one allele was pending
Patients were either classified as PKU or mild hyperphe-
nylalaninaemia (MHP) by the need of dietary restriction of
daily phenylalanine intake versus a free diet according to
information provided by the referring centers.
Results
Of the 147 individuals included in this analysis, 134 were
classified as PKU, while 13 were MHP. Full genotype,
phenylalanine levels before diet, actual patient age as well
as population background are shown in supplementary
Table 1.
Disease causing mutations were identified on 290 alleles
(98.6 %). We were able to detect both mutations in 143
patients while in four patients only one mutation could be
identified, despite additional MLPA analysis. Among our
cohort a total of 62 different mutations were identified; 13
mutations with an allele frequency ≥1.7 % are shown in
Table 1. Fourty nine mutations had an allele frequency of less
than 1.7 %; of these 31 mutations were detected on single
alleles (suppl. Table 1).
Thirty eight patients carried known null mutations on
both alleles, excluding BH4 responsiveness in 26 % of this
cohort (group 1) (Fig. 1). Thirteen patients carried one of the
following four mutations that have been reported with
consistent BH4 responsiveness p.D129G (c.386A>G),
p.A300S (c.898G>T), p.I306V (c.916A>G) and p.E390G
(c.1169A>G), on at least one allele, indicating a high proba-
bility of BH4 responsiveness in 9 % of our cohort (group 2).
Fifty four patients carried mutations with residual activity on
at least one allele accounting for 36 % of our cohort (group 3),
42 patients were carrying mutations of unknown residual
activity on both alleles or in functional hemizygosity repre-
senting 29 % of this cohort (group 4). Of the four patients
with an unidentified mutation on the second allele one
could be assigned to group 2 while three had to be assigned
to group 4.
Novel mutations
Five novel mutations were detected in seven patients in our
cohort of patients: IVS4+6T>A (c.441+6T>A), p.H290Y
(c.868C>T), IVS8-2A>G (c.913-2A>G), p.A322V
(c.965C>T) and p.I421S (c.1262T>G). They all were found
in patients of central European origin. Family segregation
was consistent with autosomal recessive inheritance and the
respective sequence alteration could not be detected in 112
control samples of central European origin. Details on in
silico and splice port analysis, full genotype and phenotype
are provided in Table 2.
Discussion
Our study cohort consisted of 147 unrelated Austrian families
(168 patients), representing about 40 % of all patients with
PAH deficiency diagnosed in Austria since 1967. Of this
cohort 24 (16 %) had a recent migration background. Within
the 294 alleles analysed we were able to identify 290 disease
causing mutations. This reflects a detection rate of 98.6 %.
In Austria five mutations account for 49.6 % of investi-
gated alleles. This is in line with other Central European
Table 2 Novel mutations of the PAH-Gene (GenBank U49897.1, NM_000277)
cDNA Gene product In silico analysis (PolyPhen2) Other allele Phenotype
HumVar Score Conserved (%) Classification
a) Missense mutations
c.868C>T p.His290Tyr (p.H290Y) 1.0 119 of 120 (99 %) Possibly damaging p.R408W PKU
c.965C>T p.Ala322Val (p.A322V) 0.87 72 of 106 (68 %) Possibly damaging p.R408W Mild PKU
(vegetarian diet)
c.1262T>G p.Ile421Ser (p.I421S) 0.948 Ile: 33 of 91 (36 %) Possibly damaging p.F39L PKU
Val: 58 of 91 (64 %)
cDNA Intron Splice Port (FGA threshold −0.5) Other allele Phenotype
FGA score wild type FGA score mutant
alleleb) Splice site mutations
c.913-2A>G 8 0.89 Below threshold p.R408W PKU
c.913-2A>G 8 0.89 Below threshold p.R158Q PKU
c.913-2A>G 8 0.89 Below threshold IVS12+1G>A PKU
c.441+6T>A 4 0.83 −0.28 p.P281.L PKU
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countries. In Northern European countries few mutations
account for high allele frequencies, e.g p.R408W (c.1222C>T)
in Baltic States (76 % in Latvia, 84 % in Estonia) and p.R408W
(c.1222C>T), p.Y414C (c.1241A>G), IVS12+1G>A (c.1315+
1G>A) in Scandinavia. Southern Europe is more heterogeneous
and the most frequent mutations, e.g., the IVS10-11G>A
(c.1066-11G>A) only covers for up to 19 % in Southern Italy,
15 % in Spain, 13 % in Greece (Zschocke 2003).
The most frequent mutation identified among our cohort
was p.R408W (c.1222C>T) with an overall allele frequency
of 23 %. It is the most prevalent mutation worldwide but its
allele frequency varies considerably within Europe in a
Northeast-Southwest devide: up to 84 % in the Baltic States
(Lilleväli et al. 1996; Pronina et al. 2003) to about 50 % in
Poland, Czech Republic and Slovakia (Jaruzelska et al. 1993;
Kadasi et al. 1995; Kozak et al. 1997), 36 % in Croatia
(Karacic et al. 2009) and less than 5 % in Southern Europe
(Italy, Greece, Spain), and complete absence in Moroccan
PKU patients (Dahri et al. 2010).
IVS12+1G>A (c.1315+1G>A) was found on 12 % of all
alleles investigated in this study. This mutation is prevalent
in Denmark (37 %) (Guldberg et al. 1993), Belgium and
Netherlands (24 %) and Scandinavia, e.g., Norway (15 %)
(Eiken et al. 1996).
p.R261Q (c.782G>A) accounted for 7 % of alleles, sim-
ilar to percentages found in Germany (6 %) (Zschocke and
Hoffman 1999), while it is found with markedly higher
prevalence of 32 % in Switzerland and 16 % in South Italy
(Daniele et al. 2007).
p.Y414C (c.1241A>G) was found in only 3.7 % of our 294
alleles, which is below the frequency of approximately 10-
18 % in Northern Europe and above the frequency of 1-3 % in
Southern Europe (Zschocke 2003).
Austrian results represent migrational shifts as well as
genetic heterogeneity among a rather small country. While
Slavonian heritage is strongly reflected by the high preva-
lence of p.R408W (c.1222C>T) there is lower prevalence of
mutations which are common in Italy or among the South
Western Europe mutational spectrum. Prevalence of more
frequent Turkish and South Eastern Europe mutations re-
flect migrational shifts that took place over the last decades
(Fig. 2).
A total of five novel mutations were identified in seven
patients: IVS8-2A>G (c.913-2A>G) n03, IVS4+6T>A
(c.441+6T>A), p.H290Y (c.868C>T), p.A322V (c.965C>T),
p.I421S (c.1262T>G).
Among the cohort of 147 patients 134 patients had PKU
while 13 patients (9.4%) hadMHP and were thus not expected
to benefit from BH4-treatment. In this cohort the following
eight mutations are assumed to determine the MHP phenotype
in compound heterozygosity: p.A104D (c.473G>A), p.D129G
(c.386A>G), p.V177L (c.529G>C), p.V245A (c.734T>C),
p.A300S (c.898G>T), p.I306V (c.916A>G), p.E390G
(c.1169a>G), p.A403V (c.1208C>T). According to published
Fig. 2 Allele frequency of
common mutations found in
Austrian patients with PAH
deficiency within the European
context. Possible origins are
indicated by the position of the
textbox on the map and allele
frequency in Austria is given in
brackets
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data on BH4 responsiveness seven of ourMHP patients would
have been assigned to group 2 (“BH4 responsive”) and six to
group 3 (“probably BH4 responsive”).
Among the cohort of 134 PKU patients prediction of BH4
responsiveness was possible in 33 %. This prediction is most
reliable for the 28.4 % of PKU patients with null mutations on
both alleles. All PKU patients with a genotype predicting a
high likelihood of BH4 responsiveness (4.5 %, n06) were
carrying the mutation p.E390G in compound heterozygosity.
The minor chance of carrying an undetected unresponsive
mutation in cis was excluded through the analysis of all
coding exons by sequencing or DGGE/Tm analysis. 35.8%
carried mutations with residual activity on at least one allele
with some chance of BH4-resonsiveness. No prediction of the
likelihood of BH4 responsiveness could be made for 31.3 %
of PKU. Remarkably the largest group (35.8 %) comprises
patients with mutations that have been classified inconsistent-
ly in different studies. There are many reasons to explain these
discrepancies that can be categorized as follows: i) modifiers
of residual PAH activity like interallelic complementation in
compound heterozygous genotypes (Leandro et al. 2006) or
discrepancies in the folding or quality control machineries
(Dipple and McCabe 2000; Pey et al. 2004); ii) inconsisten-
cies of test protocols and definitions (Zurflüh et al. 2008); or
iii) false test results, e.g., due to the impact of intra- and
interindividual variability of intestinal BH4 absorption and
blood phe levels (Zurflüh et al. 2008; Trefz et al. 2009). This
illustrates that the identification of BH4 responsive patients
cannot be based on mutational analysis alone. Better harmo-
nization of BH4 loading tests is needed and the consideration
of alternative test methods like challenge with labeled or
unlabeled phenylalanine may be reasonable. Currently a pro-
spective national trial comparing the BH4 loading test as
recommended by the European working group for phenylke-
tonuria (Blau et al. 2009) followed with a standardized phe-
nylalanine challenge is conducted with patients out of this
study cohort among Austria.
By using the Hardy-Weinberg formula Zurflüh et al. in
2008, postulated a frequency of 55 % of BH4 responsive-
ness in European populations (range 17-79 %, lowest in
Baltic Countries, highest in Spain). This number could be
an overestimate for Austria as in this scenario all patients
out of group 3 and one third of patients out of group 4
would have to show BH4 responsiveness. A standardized
BH4 loading test remains essential to finally assess BH4
responsiveness.
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